AA
VKTX icon

Ancora Advisors’s Viking Therapeutics VKTX Stock Holding History

Ancora Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2K Buy
570
+400
+235% +$12.9K ﹤0.01% 1291
2026
Q1 		$5.53K Hold
170
– – ﹤0.01% 1947
2025
Q4 		$5.98K Sell
170
-1
-0.6% -$35 ﹤0.01% 1921
2025
Q3 		$4.49K Sell
171
-2
-1% -$60 ﹤0.01% 1517
2025
Q2 		$4.58K Hold
173
– – ﹤0.01% 1506
2025
Q1 		$4.18K Hold
173
– – ﹤0.01% 1455
2024
Q4 		$6.96K Sell
173
-40
-19% -$2.28K ﹤0.01% 1401
2024
Q3 		$13.5K Buy
213
+43
+25% +$2.52K ﹤0.01% 1266
2024
Q2 		$9.01K Buy
+170
New +$11.1K ﹤0.01% 1323

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ancora Advisors's VKTX Position: Q2 2026 in Review

Ancora Advisors increased its Viking Therapeutics (VKTX) stake by 235% in Q2 2026, buying an estimated $12.9K and bringing the position to 570 shares worth $22.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Ancora Advisors first reported a position in VKTX in Q2 2024 and has held it in 9 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Ancora Advisors held 570 shares of Viking Therapeutics worth $22.2K as of Q2 2026.
  • Ancora Advisors bought 400 Viking Therapeutics shares in Q2 2026, an estimated $12.9K.
  • Viking Therapeutics made up ﹤0.01% of Ancora Advisors's portfolio in Q2 2026, its #1291 holding.
  • Ancora Advisors first reported a position in Viking Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.